Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: GlobeNewswire
MARLBOROUGH, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, announced that Nature Methods, one of the world’s leading scientific journals, has selected spatial proteomics as its prestigious “Method of the Year 2024”, recognizing the transformative potential of this approach in advancing biological research and medicine. As a global leader in spatial proteomics, with the industry’s largest installed base of 1300 instruments and nearly 1600 publications citing its technologies, Akoya celebrates this milestone as a testament to the technology’s impact and reaffirms its dedication to driving innovation in this rapidly evolving field. Spatial proteomics provides scientists with the ability to map the spatial distribution of proteins within cells and tissues, revealing insights into cellular mechanisms, tissue architecture, and disease progression. Its applications span oncology, immunotherapy, neuroscience, drug d
Show less
Read more
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsGlobeNewswire
- Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone [Yahoo! Finance]Yahoo! Finance
- Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Akoya Biosciences, Inc. (NASDAQ: AKYA) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $3.00 price target on the stock, down previously from $4.00.MarketBeat
AKYA
Earnings
- 11/14/24 - Miss
AKYA
Sec Filings
- 12/13/24 - Form 8-K
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- AKYA's page on the SEC website